VEA
CGEM icon

Virtus ETF Advisers’s Cullinan Oncology CGEM Stock Holding History

Virtus ETF Advisers’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,828
Closed -$71K – 496
2024
Q4 		$71K Buy
5,828
+1,600
+38% +$23K 0.03% 365
2024
Q3 		$70.8K Buy
4,228
+75
+2% +$1.33K 0.03% 426
2024
Q2 		$72.4K Sell
4,153
-6,028
-59% -$128K 0.04% 427
2024
Q1 		$173K Sell
10,181
-698
-6% -$10.8K 0.09% 297
2023
Q4 		$111K Buy
10,879
+2,475
+29% +$21.9K 0.07% 329
2023
Q3 		$76.1K Sell
8,404
-835
-9% -$8.7K 0.05% 370
2023
Q2 		$99.4K Buy
9,239
+756
+9% +$8.03K 0.06% 383
2023
Q1 		$86.8K Sell
8,483
-3,268
-28% -$36K 0.05% 370
2022
Q4 		$124K Buy
11,751
+3,065
+35% +$37.2K 0.06% 410
2022
Q3 		$111K Buy
8,686
+66
+0.8% +$889 0.04% 408
2022
Q2 		$111K Sell
8,620
-1,321
-13% -$15K 0.04% 404
2022
Q1 		$104K Sell
9,941
-595
-6% -$8.04K 0.05% 297
2021
Q4 		$163K Buy
10,536
+3,611
+52% +$72K 0.06% 317
2021
Q3 		$156K Sell
6,925
-356
-5% -$9.52K 0.07% 333
2021
Q2 		$187K Buy
+7,281
New +$224K 0.08% 376

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Virtus ETF Advisers's CGEM Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Cullinan Oncology (CGEM) in Q1 2025, closing a stake of 5,828 shares — an estimated $71K sold.

Virtus ETF Advisers first reported a position in CGEM in Q2 2021 and held it in 15 quarters. The position peaked at $187K in Q2 2021. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Cullinan Oncology position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,828 Cullinan Oncology shares in Q1 2025, an estimated $71K.
  • Virtus ETF Advisers first reported a position in Cullinan Oncology in Q2 2021 and held it in 15 quarters.
  • Virtus ETF Advisers's Cullinan Oncology position peaked at $187K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.